Эрлотиниб-тл - analogs
Components: Erlotinib |
|||||||||
Pharmgroups: Antitumor agents - protein kinase inhibitors |
|||||||||
Prices in pharmacies: — Instructions Эрлотиниб-тл | |||||||||
|
ⓘ✘Enter drugs for проверки взаимодействовий through a quick button search . Water for injections ✘ (incl) ВитаМишки Multi+йод+холин ✘ (incl) Ecomer ✘ (incl) Gopten ✘ (incl) Nutrilite Fit H20 Концентрат витаминного напитка со вкусом персика ✘ (incl) Ferric III oxyhydroxide sacharose-dextrane complex ✘ (incl) Гепавир ✘ (incl) Indapamide ✘ (incl) Ivabradin Canon ✘ (incl) Octavi ✘ (incl) Nazospray ✘ (incl) Insulin Semilente «WO-S» ✘ (incl) Clindovit ✘ (incl) Valusal ✘ (incl) Pentrexyl ✘ |
|
ⓘ✘ diseases to evaluate contraindications and side effects through a quick search. |
Начиная работу с сервисом, вы принимаете соглашение пользователя. Kiberis do not replace the doctor!
Similar | Complete analog ⓘ✘Аналоги препарата с полностью совпадающими действующими веществами |
Prices in pharmacies |
≈100% | Tarceva neutral | 838€ |
≈100% | Tarlenib neutral | — |
≈100% | Erlotinib neutral | — |
≈100% | Erlotinib - native neutral | — |
≈100% | Erlotinib hydrochloride neutral | — |
-
Similar
Prices in
pharmaciesAnalogs by action ⓘ✘Analogues of the drug according to its degree of similarity with other drugs that are not direct analogues
- 53% 2535.2€ Alecensa neutral [Alectinib]
- 45% — Осимертиниб neutral [Osimertinib]
- 45% 637.5-902.1€ Giotrif neutral [Afatinib]
- 45% — Zykadia neutral [Ceritinib]
- 45% — Осимертиниба мезилат neutral [Osimertinib]
- 45% 5550€ Tagrisso neutral [Osimertinib]
- 39% — Sunitinib neutral [Sunitinib]
- 39% 2016.2€ Sunitinib-nativ neutral [Sunitinib]
- 38% 1114€ Iressa neutral [Gefitinib]
- 38% — Gefitinib neutral [Gefitinib]
- 35% — ИСПОЛАТ neutral [Pemetrexed]
- 35% — Pemetrexed disodium neutral [Pemetrexed]
- 35% — Verotrexed neutral [Pemetrexed]
- 35% 993.9-2945.6€ Caprelsa neutral [Vandetanib]
- 35% — Пеметрекседа динатрия гептагидрат neutral [Pemetrexed]
- 35% 407.7€ Pemetrexed neutral [Pemetrexed]
- 35% 807.2-809.8€ Итулси neutral [Palbociclib]
- 35% 447.2-480€ Alimta neutral [Pemetrexed]
- 35% — Pemetrexed-nativ neutral [Pemetrexed]
- 35% 1199.1€ Risarg neutral [Ribociklib]
- 35% — Пеметрексед Канон neutral [Pemetrexed]
- 35% — Фолитрекс neutral [Pemetrexed]
- 35% — Пеметрексед-промомед neutral [Pemetrexed]
- 35% — Pemetrexed J neutral [Pemetrexed]
- 35% — Пемджем neutral [Pemetrexed]
- 35% 76.2-377.7€ Пемелан neutral [Pemetrexed]
- 35% — Pemetrexed-TL neutral [Pemetrexed]
- 35% 798-825€ Ibrance neutral [Palbociclib]
- 35% — Пеметрексед-ДЕКО neutral [Pemetrexed]
- 35% — Антифолат neutral [Pemetrexed]
- 35% — Пеметрексед-Рус neutral [Pemetrexed]
- 35% — Пеметрексед-Келун-Казфарм neutral [Pemetrexed]
- 35% — Пеметрекседа динатрия гемипентагидрат neutral [Pemetrexed]
- 34% 862.9€ Vargatef neutral [Nintedanib]
- 33% — Verzenio neutral [Abemaciclib]
- 33% — Sorafenib neutral [Sorafenib]
- 33% — Гефитиниб-промомед neutral [Gefitinib]
- 33% — Гефитиниб-Рус neutral [Gefitinib]
- 32% 3936.6€ Кабометикс neutral [Cabozantinib]
- 31% — Лорвиква neutral [Lorlatinib]
- 30% 1732.5€ Lenvima neutral [Lenvatinib]
- 30% — Сунитиниба малат neutral [Sunitinib]
- 29% 830-1485.8€ Nexavar neutral [Sorafenib]
- 29% — Сорафениба тозилат neutral [Sorafenib]
- 29% — Сорафениб геми-тозилат моногидрат neutral [Sorafenib]
- 29% — Сорафениб-натив neutral [Sorafenib]
- 29% — Сорафениб-АМЕДАРТ neutral [Sorafenib]
- 29% — Флутриксан neutral [Sorafenib]
- 29% — Сорафениб-промомед neutral [Sorafenib]
- 28% 1274.7€ Tyverb neutral [Lapatinib]
Learn more about the selection of analogues
- The drug has «Эрлотиниб-тл» 6 full analogs, the cheapest - Tarceva (838€); 51 analog by action, the most similar - Alecensa (2535.2€).
- Medical online service has selected the best substitutes for Эрлотиниб-тл based on its instructions, components, pharmaceutical groups and practical application.
- The table shows the prices of Эрлотиниб-тл analogues to choose the cheapest pills.
- If you have introduced other drugs for registration, substitutes are selected taking into account the assessment of interactions and safety.
- Sometimes, due to the presence of dangerous interactions, it is necessary to use drugs that are similar in effect, sometimes even from different pharmacological groups.